Peroxiredoxin-5 is a negative survival predictor in ovarian cancer.

Objectives: Peroxiredoxins (PRDXs) constitute a family of antioxidant enzymes which are also involved in the process of carcinogenesis.They are composed of six identified isoforms (PRDX-1-6) and are supposed to play different roles in tumor progression, depending on type of cancer and member of the PRDX family. The aim of the study was to assess the prognostic value of PRDXs in ovarian cancer. Material and methods:a dataset of patients with ovarian cancer from The Cancer Genome Atlas was analyzed. Expression of PRDX-1 to 6 mRNA was evaluated in 260 samples.The prognostic value of PRDXs was assessed using the Cox regression model which included the following clinical and pathological data: age, clinical stage, tumor grade, and residual disease. Results: Within the PRDXs family, only higher expression of PRDX-5 was associated with worse overall survival both, in unselected patients and >50-year-olds. PRDX-5 expression and residual disease were independent negative prognostic factors of patient survival. Conclusions: PRDX-5 is a negative predictor of survival in ovarian cancer.